BTIG Upgrades T2 Biosystems to Buy

Sep 04, 2015

|

NEW YORK (GenomeWeb) – Investment firm BTIG upgraded shares of molecular diagnostics firm T2 Biosystems, citing the market potential for a bacteria sepsis panel the company has under development.

Analyst Karen Koski upgraded T2 to a Buy rating from Neutral, putting a $16 target price on the company's shares. During late morning trading Friday, T2 stock was trading at $11.19.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Search Decisions

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

The Mouse of the Situation

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

Pain Targeted

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

Science Presents Malaria Cell Atlas, More

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.

Menu